Zobrazeno 1 - 10
of 33
pro vyhledávání: '"Benoit You"'
Autor:
Eleni Karamouza, Rosalind M. Glasspool, Caroline Kelly, Liz-Anne Lewsley, Karen Carty, Gunnar B. Kristensen, Josee-Lyne Ethier, Tatsuo Kagimura, Nozomu Yanaihara, Sabrina Chiara Cecere, Benoit You, Ingrid A. Boere, Eric Pujade-Lauraine, Isabelle Ray-Coquard, Cécile Proust-Lima, Xavier Paoletti
Publikováno v:
Cancers, Vol 15, Iss 6, p 1823 (2023)
(1) Background: Cancer antigen 125 (CA-125) is a protein produced by ovarian cancer cells that is used for patients’ monitoring. However, the best ways to analyze its decline and prognostic role are poorly quantified. (2) Methods: We leveraged indi
Externí odkaz:
https://doaj.org/article/3d6ea15b1a234135a95e0b9e7a424411
Autor:
Ambroise Lauby, Olivier Colomban, Pauline Corbaux, Julien Peron, Lilian Van Wagensveld, Witold Gertych, Naoual Bakrin, Pierre Descargues, Jonathan Lopez, Vahan Kepenekian, Olivier Glehen, Charles Andre Philip, Mojgan Devouassoux-Shisheboran, Michel Tod, Gilles Freyer, Benoit You
Publikováno v:
Cancers, Vol 14, Iss 1, p 98 (2021)
Ovarian cancer is the gynecological cancer with the worst prognosis and the highest mortality rate because 75% of patients are diagnosed with advanced stage III–IV disease. About 50% of patients are now treated with neoadjuvant chemotherapy followe
Externí odkaz:
https://doaj.org/article/a2929bd7a3ec45a7b50b8e37fc9ad34a
Autor:
Thibaut Reverdy, Christophe Sajous, Julien Péron, Olivier Glehen, Naoual Bakrin, Witold Gertych, Jonathan Lopez, Benoit You, Gilles Freyer
Publikováno v:
Cancers, Vol 12, Iss 9, p 2414 (2020)
Ovarian tumor is the gynecological cancer associated with the highest mortality. Most diseases are diagnosed at an advanced stage, which impairs the chances of prolonged complete remission. The standard front-line treatment of advanced stages combine
Externí odkaz:
https://doaj.org/article/581fb489cd8f4010ae84723cbe24aabf
Autor:
Philippe Follana, Pierre Combe, Eric Pujade-Lauraine, Alexandra Leary, Patrick Robelin, Gilles Freyer, Michel Fabbro, Nathalie Bonichon-Lamichhane, Christophe Desauw, Olivier Colomban, Christophe Louvet, Jean-Emmanuel Kurtz, Gwenael Ferron, M. Leheurteur, Annick Chevalier-Place, Benoit You, Gaëtan de Rauglaudre, Isabelle Ray-Coquard, Jean-Pierre Lotz, Sophie Abadie-Lacourtoisie, Florence Joly, Francesco Del Piano, Michel Tod
Publikováno v:
Clinical Cancer Research. 26:4625-4632
Purpose: In patients with ovarian cancer receiving neoadjuvant chemotherapy, the first-line treatment success will depend on both the tumor-primary chemosensitivity and the completeness of interval debulking surgery (IDS). The modeled CA-125 ELIMinat
Autor:
Mathilde Cancel, Oana Pop, Alain Lortholary, C.B. Levaché, Daniel Pissaloux, Magali Provansal, Elsa Kalbacher, Rémy Largillier, Amélie Anota, Audrey Lardy-Cleaud, Jérôme Meunier, Christophe Louvet, Anne-Claire Hardy-Bessard, Aurélie Houlier, Marie-Ange Mouret-Reynier, Fabien Brocard, Benoit You, Anne Floquet, Cyril Abdeddaim, Aude-Marie Savoye, Isabelle Ray-Coquard, Alain Zannetti, Laurence Venat-Bouvet, Isabelle Treilleux, Olivier Tredan, Jean-Sebastien Frenel
Publikováno v:
Gynecologic Oncology
Gynecologic Oncology, 2022, 164 (1), pp.18-26. ⟨10.1016/j.ygyno.2021.09.024⟩
Gynecologic Oncology, 2022, 164 (1), pp.18-26. ⟨10.1016/j.ygyno.2021.09.024⟩
Objective To evaluate the efficacy and safety of regorafenib versus tamoxifen in platinum-sensitive ovarian cancer biological recurrence, defined by CA-125 increase without radiological (RECIST criteria) or symptomatic evidence of progression. Patien
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::442e0efad461a61c2ee12df093873312
https://hal.archives-ouvertes.fr/hal-03868128
https://hal.archives-ouvertes.fr/hal-03868128
Autor:
Michel Tod, Benoit You, Christian Kurzeder, Jacobus Pfisterer, Julien Péron, Alexandra Leary, Gilles Freyer, Anne-Claire Hardy-Bessard, Andreas du Bois, Alexander Burges, Olivier Colomban, Isabelle Ray-Coquard, Alain Lortholary
Publikováno v:
Clinical Cancer Research. 25:5342-5350
Purpose: Regarding cancer antigen 125 (CA-125) longitudinal kinetics during chemotherapy, the actual predictive value of the Gynecologic Cancer Intergroup (GCIG) CA-125 response criterion is questioned. The modeled CA-125 elimination rate constant KE
Publikováno v:
Gynécologie Obstétrique Fertilité & Sénologie. 47:222-237
Medical treatment of ovarian cancer is based on chemotherapy. Most patients, regardless of the initial stage of their disease, will need to be treated (grade A). Standard treatment relies on a carboplatin and paclitaxel combination (grade A). For adv
Publikováno v:
Oral Poster – TAPED.
Introduction In VELIA (Phase 3), veliparib with carboplatin/paclitaxel (CP), followed by veliparib maintenance (veliparib-throughout) led to improved progression-free survival (PFS) vs CP alone (control). This exploratory analysis assessed the progno
Autor:
Julien Péron, Michel Tod, Christophe Sajous, Adrian Cook, Gilles Freyer, Timothy J. Perren, Olivier Colomban, Alexandra Leary, Benoit You
Publikováno v:
JNCI Cancer Spectrum
Bevacizumab is approved as a maintenance treatment in first-line setting in advanced-stage III-IV ovarian cancers, because GOG-0218 and ICON-7 phase III trials demonstrated progression-free survival benefits. However, only the subgroup of patients wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::23c797afc88f0ce5d9462aa2626a5708
Autor:
Jérôme Meunier, Florence Joly, Joël Lachuer, E. Malaurie, Marie-Christine Kaminsky, Dominique Berton-Rigaud, Jérôme Alexandre, Gaëtan de Rauglaudre, Coraline Dubot, Michel Tod, Patrick Robelin, Olivier Colomban, Alexandra Leary, Gwenael Ferron, Isabelle Ray-Coquard, Alain Lortholary, Annick Chevalier-Place, Salima Hamizi, Benoit You, N. Raban, Pierre Combe
Publikováno v:
Gynecologic Oncology
Gynecologic Oncology, 2020, 159, pp.256-263. ⟨10.1016/j.ygyno.2020.07.021⟩
Gynecologic Oncology, Elsevier, 2020, 159, pp.256-263. ⟨10.1016/j.ygyno.2020.07.021⟩
Gynecologic Oncology, 2020, 159, pp.256-263. ⟨10.1016/j.ygyno.2020.07.021⟩
Gynecologic Oncology, Elsevier, 2020, 159, pp.256-263. ⟨10.1016/j.ygyno.2020.07.021⟩
International audience; Objective: MicroRNAs (miRNAs) are promising biomarkers in ovarian cancer. Their kinetics during treatment might be useful for monitoring disease burden, and guiding treatments in patients treated with peri-operative chemothera